Organization (Industry)
Revance Therapeutics, Inc.
ClinicalTrials.gov lists Revance Therapeutics, Inc. as lead sponsor of 29 trials. It has 4 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Revance Therapeutics, Inc.: 29 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dystonia | 4 |
| Fasciitis, Plantar | 3 |
| Torticollis | 3 |
| Blepharospasm | 1 |
| Headache | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 1 |
| 2016 | 4 |
| 2015 | 3 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: none of the 29 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Botulinum Toxins, Type A | Fasciitis, Plantar | Phase 2 | 1 |
| DAXI 120 U | Fasciitis, Plantar | Phase 2 | 1 |
| daxibotulinumtoxin type A | Fasciitis, Plantar | Phase 2 | 1 |
| DAXI 80 U | Fasciitis, Plantar | Phase 2 | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| BOTULINUM TOXIN TYPE-A | 15 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 67% hit target (n=9) | 56% on time (n=9) |
Journals published in (14)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] | 6 |
| Movement disorders clinical practice | 2 |
| Toxins | 2 |
| Clinical ophthalmology (Auckland, N.Z.) | 1 |
| Drugs | 1 |
Showing 5 of 14 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 35 | 7 | 2025-03-25 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 2 | 2026-07-31 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| REVANCE THERAPEUTICS, INC. | Newark, US | FDA | |
| Revance Therapeutics, Inc. | Moffett Field, US | FDA |
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Syneos Health (United States) | Uses vendor | 2 |
| Montefiore Medical Center | Co sponsors trial with | 1 |
| Ki Health Partners. LLC | Co sponsors trial with | 1 |
| The Los Angeles Headache Center | Co sponsors trial with | 1 |
Latest dated events (72)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-31 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-07-08 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-05-01 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-03-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 72 events.
Biomarker capability evidence (1)
| Gene | Role | Evidence |
|---|---|---|
| SH2D1A | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.